AzTrials
AzTrials

SpondyloarthritisSPARKNCT06462937

A Digital Exercise Intervention in Patients With Spondyloarthritis

A study testing Exercise with supervision and Exercise without supervision in people with Spondyloarthritis and Exercise, run by Diakonhjemmet Hospital at 1 site in Norway.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This protocol describes a 6-month randomised, controlled exercise trial in patients with axial spondyloarthritis (axSpA) with re-randomization after 3-months. The primary outcome of the trial (disease activity) will be evaluated at 3-months. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Spondyloarthritis, Exercise
What is being tested?
Exercise with supervision and Exercise without supervision
Could I receive a placebo?
No, everyone receives an active treatment
How many people
260 participants
Where
1 siteNorway
Study dates
1 Jul 2024to 1 Aug 2030
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • axSpA diagnosis within the last two years by a rheumatologist according to the ASAS criteria of 2009
  • active disease (ASDAS > 1.3)

Who cannot join

  • Active uveitis.
  • CRP > 30.
  • Former or current use of bDMARDs.
  • Pregnancy or planned pregnancy within 6 months from inclusion.
  • Absolute and relative contradictions to high intensity exercise according to the American College of Sports Medicine (ACSM)
  • Other serious disease such as cancer.
  • Patients incapable to follow the protocol or the control set-up with remote monitoring.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sella A Provan, Professor contact

4791582581

SellaProvan@gmail.com

Birgitte Nellemann, PhD contact

4747957020

birgittenellemann@gmail.com

Norway1 site, 1 recruiting
  • Diakonhjemmet hospital

    Oslo

    Birgitte Nellemann, 4747957020

    Recruiting

Other trials in Norway

About this study

Official title: The SPARK Trial: a Digital Exercise Intervention in Patients With Spondyloarthritis

This protocol describes a 6-month randomised, controlled exercise trial in patients with axial spondyloarthritis (axSpA) with re-randomization after 3-months. The primary outcome of the trial (disease activity) will be evaluated at 3-months. The exercise programme on trial comprises high intensity interval training (HIIT), muscular strength exercise and aerobic physical activity sessions of specified duration, frequency, and intensity. It also includes brief knowledge videos to empower the patient. The intervention is remotely delivered by the SPARK application with personalised follow-up including monitoring to ensure exercise progression and adherence to exercise intensity. The SPARK application is built on a platform delivered by ABEL Technologies (trademark) and is customised for patients with axSpA.

Read the detailed description

Main objectives: To assess if a digital personally tailored exercise program with remote follow-up can reduce disease activity measured by ankylosing spondylitis disease activity score (ASDAS) in patients with recently diagnosed axial spondyloarthritis (axSpA).

Main inclusion criteria Adults (> 18 years) with clinical diagnosis from a rheumatologist of axSpA within the last 2 years of inclusion also fulfilling the ankylosing spondylitis disease activity score (ASAS) classification criteria, who are biologic disease modifying anti-rheumatic drugs (bDMARD) naïve, and have an active disease (ASDAS ≥ 1.3)

Main exclusion criteria:

Active iridocyclitis, c-reactive protein (CRP) > 30, contraindication to high intensity interval training

Primary outcome Proportion of participants in ASDAS inactive (ASDAS < 1.3) at 3 months

Number of participants: 260 (with an anticipated drop-out rate of 15%)

Study design: A two-arm multi-centre, clinical trial, randomization 1:1 to either digital exercise intervention with remote follow-up or usual care.

Intervention: Exercise delivered through an application and with personalised follow-up by a coach through remote sessions (the participant and SPARK-coach are not at the same physical location) weekly. The exercise is progressively tailored to the fitness level of each participant. The program consists of 5 session per week on 3 different days including: two sessions with HIIT, 2 sessions with strength exercise, and one session with an aerobic exercise at moderate intensity. Goal for HIIT is 10 minutes two times per week at 85-95% of maximal heart rate (20 minutes in total). The exercise will be performed at a location of the participants' choice and data will be logged by a sports watch.

Efficacy assessments: ASDAS disease activity measure (4 patient reported questions and measure of CRP), Bath ankylosing spondylitis disease activity index (BASDAI).

Physical measure: cardiorespiratory fitness, in a subset of participants direct cardiopulmonary testing, muscular strength tests.

Psychological measures: Warwick and Edinburgh mental wellbeing scale (WEMWBS), EuroQol (EQ5D).

Medication: use of bDMARDs, use of NSAID

Safety assessments General physical examination and vital signs, laboratory tests as a part of usual clinical care, record of adverse events and serious adverse events, magnetic resonance imaging (MRI).

Being tested
Exercise with supervision, Exercise without supervision
Keywords
Remote, Digital, High intensity interval training
Medical subject headings
Spondylarthritis, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise with supervisionBehavioural

    Remote exercise will be administered with digital supervision. The Exercise group will receive a personalised program with individual adaptations aiming to perform 3 exercise sessions per week including HIIT, strength exercise and moderate intensive aerobic exercise. Participants will consult their rheumatologist parallel to the SPARK trial.

  • Exercise without supervisionBehavioural

    Remote exercise will be administered without digital supervision. Participants will receive a standard exercise program fulfilling the exercise protocol requirements, the exercise program will progress. But there will be no direct contact between the participant and the coach. Participants will consult their rheumatologist parallel to the SPARK trial.

Study groups in NCT06462937
Study groupRoleWhat they receive
Exercise with personal supervision 0-3 monthsExperimentalExercise
Receives: Behavioral: Exercise with supervision
Control 0-3 monthsNo interventionUsual care
Exercise with personal supervision 3-6 monthsExperimentalExercise
Receives: Behavioral: Exercise with supervision
Exercise without personal supervision 3-6 monthsActive comparatorExercise
Receives: Behavioral: Exercise without supervision

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease activity 3 months

    Number of participants in ASDAS inactive (ASDAS < 1.3) at 3 months

    Measured: 3 months

Secondary outcomes (24)
  1. Biologic disease modifying anti-rheumatic drugs 3 months

    Number of participants on biologic disease modifying anti-rheumatic drugs (bDMARD) at 3 months

    Measured: 3 months

  2. Disease activity 6 months

    Number of participants in ankylosing spondylitis disease activity score (ASDAS) inactive (ASDAS < 1.3) at 6 months

    Measured: 6 months

  3. Proportion of participants using non-steroidal anti-inflammatory drugs

    Usage of non-steroidal anti-inflammatory drugs (NSAIDs)

    Measured: 3 and 6 months

  4. Bath ankylosing spondylitis metrology index

    Physical function measured by Bath ankylosing spondylitis metrology index (BASMI). Range 0-10 where 0= no functional impairment 10=very significant impairment

    Measured: 3 and 6 months

  5. Bath ankylosing spondylitis function index

    Physical function measured by Bath ankylosing spondylitis function index (BASFI). Scale range 0-10, where 0= no functional impairment 10=very significant impairment

    Measured: 3 and 6 months

  6. Ankylosing spondylitis Performance Index

    Physical function measured by Ankylosing spondylitis Performance Index (ASPI). Continuous variable in units of minutes. The functional level is inversely proportional to the number of minutes.

    Measured: 3 and 6 months

  7. Physical fitness

    Indirect exercise test on a tread-mill until exhaustion. Measured in oxygen uptake ml/min/kg.

    Measured: 3 and 6 months

  8. Physiological effects of exercise on inflammation measured by CRP

    Effect of exercise on CRP

    Measured: 3 and 6 months

  9. Physiological effects of exercise on blood pressure

    Effect of exercise on blood pressure

    Measured: 3 and 6 months

  10. Physiological effects of exercise on weight

    Effect of exercise on weight in kg

    Measured: 3 and 6 months

  11. Physiological effects of exercise on muscle mass

    Effect of exercise on body composition measured as percentage muscle mass

    Measured: 3 and 6 months

  12. Physiological effects of exercise on adipose tissue

    Effect of exercise on body composition measured as percentage adipose tissue

    Measured: 3 and 6 months

  13. Safety measures of exercise Spine

    Safety measures: MRI spine in a subset of participants at baseline and after 3 months of exercise. Level of inflammation scored by Canadian Spondyloarthritis Research Consortium score (SPARCC). High score represents more inflammation. The minimum score 0, max score 108

    Measured: 3 and 6 months

  14. Safety measures of exercise Sacroiliac joints

    Safety measures: MRI sacroiliac joints in a subset of participants at baseline and after 3 months of exercise. Level of inflammation scored by Canadian Spondyloarthritis Research Consortium (SPARCC). High score represents more inflammation. The minimum score 0, max score 72

    Measured: 3 and 6 months

  15. Effects of exercise on mental wellbeing

    Quality of life Warwick Edinburgh Mental Wellbeing Scale WEMWBS). Range 14-70. A higher score indicates greater mental well-being

    Measured: 3 and 6 months

  16. Effects of exercise on quality of life

    Quality of life EQ5D. Range -0.59 to 1, where 1 is the best possible health state

    Measured: 3 and 6 months

  17. Work presenteeism

    Health economy measures: work presenteeism expressed in percentage (%) measured by Work Productivity and Activity Impairment Questionnaire (WPAI)

    Measured: 3 and 6 months

  18. Work absenteeism

    Health economy measures: work absenteeism expressed in percentage (%) measured by Work Productivity and Activity Impairment Questionnaire (WPAI)

    Measured: 3 and 6 months

  19. Work impairment

    Health economy measures: work overall impairment expressed in percentage (%) measured by Work Productivity and Activity Impairment Questionnaire (WPAI)

    Measured: 3 and 6 months

  20. Functional impairment

    Health economy measures: functional impairment expressed in percentage (%) measured by Work Productivity and Activity Impairment Questionnaire (WPAI)

    Measured: 3 and 6 months

  21. Contact with the Healthcare services

    Health economy measures: Contact with the health care services. Self reported as number of visits to general practitioner, specialist healthcare and/or physiotherapist during past 3 months

    Measured: 3 and 6 months

  22. Sleep quality

    Questionnaire on sleep quality: Pittsburgh Sleep Questionnaire. Global score ranges from 0 to 21 and higher scores indicate poorer sleep quality.

    Measured: 3 and 6 months

  23. Physical activity level

    Physical activity level measured for one week at baseline, 3 months and 6 months by a movement sensor. (Actigraph). The score will be presented as Metabolic Equivalents. A high score represents more movement

    Measured: Baseline, 3 and 6 months

  24. Adverse events

    We collect information of adverse events including any discomfort, muscle pain, joint pain, joint swallowing, dyspnoe, chest pain, ancle sprain, pain in a muscle group, pain in entheses, broken bones, infections. Participants report every 4 weeks through out the study, and SPARK coaches report for the participants at every follow-up.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2024
  2. Study start1 Jul 2024
  3. Primary completion1 Aug 2027 (estimated)
  4. Study completion1 Aug 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Crossover
Model description
Baseline: randomization to intervention (Exercise) or control (Usual care) 1:1. 3 months: randomization to intervention (Exercise remotely delivered plan with personalised weekly follow-up) or control (Exercise remotely delivered plan without weekly follow-up)
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
260 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06462937
Sponsor's protocol ID
DS00735
Acronym
SPARK
Status last verified
Aug 2026
First submitted
13 May 2024
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data will only be shared upon resonable request

Publications

  • Nellemann B, Fongen C, Dagfinrud H, Berg IJ, Kristianslund EK, Sexton J, Norden KR, Lillegraven S, Osteras N, Jorgensen TS, Carmona L, Sveaas SH, Provan SA. Remote personalised exercise in axial spondyloarthritis: the SPARK trial - protocol for a 6-month randomised controlled trial. BMJ Open. 2026 Mar 30;16(3):e112420. doi: 10.1136/bmjopen-2025-112420.

    PubMed 41916634

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in